<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02887807</url>
  </required_header>
  <id_info>
    <org_study_id>2012-753</org_study_id>
    <nct_id>NCT02887807</nct_id>
  </id_info>
  <brief_title>CYclosporine A in Shockable Out-of-hospital Cardiac Arrest ResUScitation</brief_title>
  <acronym>CYRUS II</acronym>
  <official_title>CYclosporine A in Shockable Out-of-hospital Cardiac Arrest ResUScitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac arrest (CA) is a public health problem in industrialized countries. The prognosis of
      these patients remains poor with significant mortality and severe neurological sequelae in
      survivors.

      The objective of the present study is to determine whether cyclosporine can improve patient
      clinical outcome after shockable CA. 520 patients with CA will be entered into a multicentre,
      randomized, placebo-controlled study. They will receive one single injection of cyclosporine
      (or placebo) prior to resuscitation. The incidence of the combined endpoint (mortality,
      irreversible brain damage informations such as bilateral abolition of N20 wave or absent
      motor response or extension to the nociceptive stimulationâ€¦) will be assessed 7 days after
      CA.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined incidence of all-cause mortality and irreversible brain damage status</measure>
    <time_frame>7 days</time_frame>
    <description>the presence of irreversible brain damage is defined by the bilateral abolition of the N20 wave on somatosensory evoked potentials recordings or the absence of motor response or extension to painful stimuli on the Glasgow Coma Scale.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Shockable Out of Hospital Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>Cyclosporine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intravenous bolus of placebo (2.5 mg/kg) at the onset of resuscitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation</intervention_name>
    <description>cardio-pulmonary resuscitation usual care of cardiac arrest</description>
    <arm_group_label>Cyclosporine A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single intravenous bolus of placebo at the onset of resuscitation</intervention_name>
    <description>cardio-pulmonary resuscitation usual care of cardiac arrest</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Witnessed out-of-hospital cardiac arrest

          -  Shockable cardiac rhythm at first medical contact (ventricular fibrillation,
             ventricular tachycardia)

        Exclusion Criteria:

          -  Evidence of trauma

          -  Evidence of pregnancy

          -  Duration of no flow more than 30 minutes

          -  Rapidly fatal underlying disease

          -  Allergy to cyclosporin A
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Argaud</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent Argaud, MD</last_name>
    <phone>472110015</phone>
    <phone_ext>+33</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michel OVIZE</last_name>
    <phone>427856570</phone>
    <phone_ext>+33</phone_ext>
    <email>michel.ovize@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Cardiologique</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent Argaud</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2016</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac arrest</keyword>
  <keyword>Shockable</keyword>
  <keyword>Cyclosporine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

